However, with there being scarce evidence regarding the impact of ferroptosis-released HMGB1 on tumor growth in vivo, it is not enough to conclude that HMGB1 plays a beneficial role in the ferroptosis-induced immune response for antitumor therapy, and further investigations are still required. Here, HMGB1 is linked to neoplasm.